Chi3l1 Is a Modulator of Glioma Stem Cell States and a Therapeutic Target in Glioblastoma

Charlotte Guetta-Terrier1, David Karambizi1, Bedia Akosman1,2

  • 1Laboratory of Cancer Epigenetics and Plasticity, Brown University, Rhode Island Hospital, Providence, Rhode Island.

Cancer Research
|April 27, 2023
PubMed

Insights

Chitinase 3-like 1 (Chi3l1) promotes glioblastoma growth by altering glioma stem cell states. Targeting Chi3l1 with antibodies inhibits tumor growth and improves survival, revealing a potential therapeutic strategy.

Area of Science:

  • Neuro-oncology
  • Cancer Biology
  • Molecular Biology

Background:

  • Chitinase 3-like 1 (Chi3l1) is highly expressed in glioblastoma.
  • Glioma stem cells (GSCs) drive tumor growth and recurrence.

Purpose of the Study:

  • To investigate the role of Chi3l1 in regulating GSC states and glioblastoma progression.
  • To identify potential therapeutic targets within the Chi3l1 pathway.

Main Methods:

  • Exposure of patient-derived GSCs to Chi3l1.
  • Analysis of cell surface markers (CD133, SOX2, CD44).
  • Assessment of intracellular signaling pathways (β-catenin, Akt, STAT3).
  • Single-cell RNA sequencing and RNA velocity analysis.
  • ATAC-seq to identify transcription factor binding.
  • Inhibition of MAZ and Chi3l1 in vivo.

Main Results:

  • Chi3l1 altered GSC markers, increasing CD44+Chi3l1+ cells and decreasing CD133+SOX2+ cells.
  • Chi3l1 induced Akt/β-catenin signaling and promoted a mesenchymal GSC state.
  • Chi3l1 increased accessibility of MAZ binding sites, enhancing GSC self-renewal.
  • Inhibition of Chi3l1 in vivo reduced tumor growth and improved survival.

Conclusions:

  • Chi3l1 interacts with CD44 on GSCs, activating signaling pathways that promote a pro-mesenchymal phenotype and enhance self-renewal.
  • Chi3l1 regulates GSC plasticity, presenting a targetable vulnerability in glioblastoma.
  • Targeting Chi3l1 offers a promising therapeutic strategy for glioblastoma treatment.

Related Concept Videos